### Contents

Preface xv  
Contributors xix  

Chapter 1: Neuroendocrine Control of Food Intake  
*Andrew A. Butler, James L. Trevaskis and Christopher D. Morrison*  

1. Introduction 1  
2. Central Nervous System Regulation of Feeding Behavior 2  
3. Neuroendocrine Factors Secreted from the Gut 2  
   3.1. Cholecystokinin 3  
   3.2. Peptide YY 5  
   3.3. Ghrelin 6  
   3.4. Amylin 7  
   3.5. Enterostatin 7  
   3.6. Glucagon-like Peptide 8  
   3.7. Bombesin Family: Bombesin, Gastrin-releasing Peptide and Neuromedin B 8  
   3.8. Oxyntomodulin 9  
   3.9. Leptin 10  
4. Neuroendocrine Indicators of Long-term Energy Balance: Leptin and Insulin 10  
   4.1. Leptin and Insulin Signaling in Diet-induced Obesity 12  
5. Summary 13  
References 13  

Chapter 2: Body Composition Assessment of Obesity  
*Wm. Cameron Chumlea*  

1. Introduction 23  
2. Overview of Body Composition Methods 24  
   2.1. Anthropometry 24  
   2.2. Weight and Stature 24  
   2.3. Body Mass Index 25  
   2.4. Abdominal Circumference 26  
   2.5. Skinfolds 27  
   2.6. Bioelectric Impedance Analysis 28
<table>
<thead>
<tr>
<th>2.7. Body Density</th>
<th>29</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.8. Total Body Water</td>
<td>29</td>
</tr>
<tr>
<td>2.9. Dual-energy x-ray Absorptiometry</td>
<td>29</td>
</tr>
<tr>
<td>3. Ethnic Differences in Body Composition</td>
<td>30</td>
</tr>
<tr>
<td>4. Available Reference Data</td>
<td>30</td>
</tr>
<tr>
<td>5. Recommendations</td>
<td>31</td>
</tr>
<tr>
<td>6. Conclusion</td>
<td>31</td>
</tr>
<tr>
<td>Acknowledgments</td>
<td>32</td>
</tr>
<tr>
<td>References</td>
<td>32</td>
</tr>
</tbody>
</table>

Chapter 3: Prevalence of Obesity and the Metabolic Syndrome

*Ali H. Mokdad and Earl S. Ford*

<table>
<thead>
<tr>
<th>1. Overweight and Obesity</th>
<th>37</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Prevention and Control Programs</td>
<td>44</td>
</tr>
<tr>
<td>3. THE Metabolic Syndrome</td>
<td>45</td>
</tr>
<tr>
<td>4. Preventive and Control Strategies</td>
<td>47</td>
</tr>
<tr>
<td>5. Future Perspectives</td>
<td>48</td>
</tr>
<tr>
<td>References</td>
<td>49</td>
</tr>
</tbody>
</table>

Chapter 4: The Genetic Contribution to Obesity

*Raul A. Bastarrachea, Jack W. Kent Jr., Jeff T. Williams, Guowen Cai, Shelley A. Cole and Anthony G. Comuzzie*

<table>
<thead>
<tr>
<th>1. Introduction</th>
<th>55</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Obesity as a Common Complex Phenotype</td>
<td>56</td>
</tr>
<tr>
<td>3. Ancient Genes in a Modern World: An Evolutionary Genetic Perspective on Obesity</td>
<td>57</td>
</tr>
<tr>
<td>4. Approaches to Obesity Gene Discovery</td>
<td>58</td>
</tr>
<tr>
<td>4.1. Candidate Gene Association Study</td>
<td>59</td>
</tr>
<tr>
<td>4.2. Genome Scan</td>
<td>59</td>
</tr>
<tr>
<td>4.3. mRNA</td>
<td>60</td>
</tr>
<tr>
<td>5. Evidence from Animal Models for the Genetic Contribution to Obesity</td>
<td>60</td>
</tr>
<tr>
<td>5.1. Monogenic Obesity</td>
<td>60</td>
</tr>
<tr>
<td>5.2. Oligogenic Obesity</td>
<td>62</td>
</tr>
<tr>
<td>6. Evidence for the Genetic Contribution to Obesity in Humans</td>
<td>63</td>
</tr>
<tr>
<td>6.1. The Genetic Contribution to Rare Forms of Human Obesity</td>
<td>63</td>
</tr>
<tr>
<td>6.2. Genetic Contribution to Common Human Obesity</td>
<td>66</td>
</tr>
<tr>
<td>7. Conclusion</td>
<td>72</td>
</tr>
<tr>
<td>Acknowledgments</td>
<td>73</td>
</tr>
<tr>
<td>References</td>
<td>73</td>
</tr>
</tbody>
</table>
Chapter 5: Etiology of Obesity: The Problem of Maintaining Energy Balance

Barry E. Levin and Deborah J. Clegg

1. Introduction: Obesity and the Concept of Defended Body Weight 83
2. Neural Control of the Defended Body Weight 85
3. Obesity and the Problem of Maintaining Body Weight 88
5. Factors That Lower the Defended Body Weight 91
6. Implications for Future Research 91
References 92

Chapter 6: Current Views of the Fat Cell as an Endocrine Cell: Lipotoxicity

Tamara Tchkonia, Barbara E. Corkey and James L. Kirkland 105
1. Introduction 105
2. Functions of Fat Tissue 105
3. Conditions Associated with Lipotoxicity 106
4. Mechanisms of Lipotoxicity 108
5. Inherent Properties of Cells Contribute to Susceptibility to Lipotoxicity 111
6. Association between Lipids and Inflammatory Responses 111
7. Mechanisms of Defense against Lipotoxicity 112
8. Preadipocytes and Fat Cells Are more Resistant than Other Cell Types to FA 114
9. Summary 116
10. Conclusions 117
Acknowledgments 118
References 118

Chapter 7: Ectopic Fat and the Metabolic Syndrome

Frederico G.S. Toledo and David E. Kelley 125
1. Introduction 125
2. Consequences of Excess Adiposity to Whole-body Glucose Homeostasis 126
3. FFA-induced Insulin Resistance 127
4. Ectopic Fat in Skeletal Muscle and Insulin Resistance 128
5. Relationships between Ectopic Fat in Liver and Insulin Resistance 129
6. Human Lipodystrophic Syndromes 130
7. Concluding Remarks 131
References 132

Chapter 8: Abdominal Obesity and the Metabolic Syndrome

Jean-Pierre Després, Isabelle Lemieux and Natalie Alméras 137
1. Introduction 137
2. Metabolic Syndrome without Hyperglycemia Predicts an Increased CHD Risk 140
## Chapter 13: Behavioral Strategies for Controlling Obesity

*Donald A. Williamson, Corby K. Martin and Tiffany M. Stewart*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Introduction</td>
<td>219</td>
</tr>
<tr>
<td>2. History of Behavioral Strategies for Controlling Obesity</td>
<td>220</td>
</tr>
<tr>
<td>2.1. Philosophy of Treatment</td>
<td>220</td>
</tr>
<tr>
<td>3. Behavioral Treatment for Adults</td>
<td>221</td>
</tr>
<tr>
<td>3.1. Approach and Outcomes</td>
<td>221</td>
</tr>
<tr>
<td>3.2. Duration of Treatment</td>
<td>221</td>
</tr>
<tr>
<td>3.3. Targets and Tools</td>
<td>221</td>
</tr>
<tr>
<td>3.4. Weight Maintenance Strategies</td>
<td>225</td>
</tr>
<tr>
<td>3.5. Special Considerations</td>
<td>226</td>
</tr>
<tr>
<td>4. Behavioral Treatment for Children and Adolescents</td>
<td>227</td>
</tr>
<tr>
<td>4.1. Approaches, Tools, and Outcomes</td>
<td>227</td>
</tr>
<tr>
<td>4.2. Reinforcement, Adherence, and Behavior Change</td>
<td>227</td>
</tr>
<tr>
<td>4.3. Social Support and Parent Training</td>
<td>228</td>
</tr>
<tr>
<td>4.4. Problem-solving</td>
<td>228</td>
</tr>
<tr>
<td>4.5. Meal Planning</td>
<td>228</td>
</tr>
<tr>
<td>4.6. Physical Activity</td>
<td>229</td>
</tr>
<tr>
<td>4.7. Special Considerations</td>
<td>229</td>
</tr>
<tr>
<td>5. Conclusions</td>
<td>230</td>
</tr>
<tr>
<td>6. Summary</td>
<td>230</td>
</tr>
<tr>
<td>References</td>
<td>231</td>
</tr>
</tbody>
</table>

## Chapter 14: Obesity Prevention

*Shiriki K. Kumanyika and Stephen R. Daniels*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Introduction</td>
<td>233</td>
</tr>
<tr>
<td>2. Defining the Task</td>
<td>234</td>
</tr>
<tr>
<td>2.1. Individual Level Perspective</td>
<td>234</td>
</tr>
<tr>
<td>2.2. Population Perspective</td>
<td>235</td>
</tr>
<tr>
<td>2.3. Goals and Priorities</td>
<td>235</td>
</tr>
<tr>
<td>3. Population-wide Approaches</td>
<td>237</td>
</tr>
<tr>
<td>3.1. Initiatives Related to Food</td>
<td>238</td>
</tr>
<tr>
<td>3.2. Initiatives Related to Physical Activity</td>
<td>238</td>
</tr>
<tr>
<td>3.3. Social Marketing</td>
<td>239</td>
</tr>
<tr>
<td>4. Prevention Targeted to Selected Population Groups</td>
<td>239</td>
</tr>
<tr>
<td>4.1. Adults</td>
<td>240</td>
</tr>
<tr>
<td>4.2. Children</td>
<td>243</td>
</tr>
<tr>
<td>5. Individually Targeted Approaches</td>
<td>247</td>
</tr>
<tr>
<td>6. Multilevel Approaches</td>
<td>247</td>
</tr>
</tbody>
</table>
Chapter 15: Orlistat and Sibutramine in the Management of Obesity

Holly Wyatt

1. Introduction 255
2. Who Is Appropriate? Criteria for Use of Weight Loss Medications 255
3. Why Do Health Care Providers Choose not to Use Weight Loss Medications? 257
4. What Weight Loss Drugs Are Available? 258
5. How Should Weight Loss in Medication Clinical Trials Be Evaluated? 259
6. Sibutramine 260
   6.1. Mechanism of Action 261
   6.2. Therapeutic Potential for Obesity 261
   6.3. Efficacy in Weight Loss Maintenance 262
   6.4. Efficacy in Managing Obesity-related Risk Factors 264
   6.5. Tolerability and Safety 265
   6.6. Special Considerations when Prescribing Sibutramine 266
7. Orlistat 266
   7.1. Mechanism of Action 267
   7.2. Therapeutic Potential for Obesity 267
   7.3. Efficacy in Weight Loss Maintenance 270
   7.4. Efficacy in Managing Obesity-related Risk Factors 270
   7.5. Tolerability and Safety 271
   7.6. Special Considerations when Prescribing Orlistat 272
8. The Future of Weight Loss Medications 272
   8.1. Sibutramine and Orlistat Usage in Adolescents 272
   8.2. Combination Therapy 273
   8.3. Continuous vs. Episodic Medication Usage 273
9. Summary 274
   References 274

Chapter 16: A Status of Drugs on the Horizon for Obesity and the Metabolic Syndrome—a Comprehensive Review 2005

Frank Greenway and George Bray

1. Introduction 281
2. Drugs Approved for Indications Other than Obesity and That Cause Weight Loss 282
   2.1. Bupropion 282
   2.2. Fluoxetine/Sertraline 283
   2.3. Zonisamide 284
   2.4. Topiramate 284
2.5. Metformin 285
2.6. Somatostatin 286
2.7. Pramlintide 287
2.8. Exenatide 287

3. Drugs in Phase III Clinical Trials with no Approval 288
3.1. Rimonabant 288
3.2. Axokine 289
3.3. Leptin 289

4. Drugs in the Early Phases of Development 290
4.1. Growth Hormone Fragment 290
4.2. Cholecystokinin 290
4.3. PYY 3-36 290
4.4. Oleoylsterone 291
4.5. Serotonin 2C Receptor Agonist 291
4.6. Neuropeptide Y Receptor Antagonists 291
4.7. Melanin Concentrating Hormone Receptor-1 Antagonist 292
4.8. Pancreatic Lipase Inhibitor 292
4.9. Glucagon-like Peptide-1 Agonists and Dipeptidyl Peptidase-4 Inhibitors 292

5. Drugs no Longer under Investigation or Withdrawn 293
5.1. β3-adrenergic Agonists 293
5.2. Ephedra 293
5.3. Phenylpropanolamine 294
5.4. Bromocriptine 294
5.5. Ecopipam 295

6. New Areas where Drugs Are Being Developed 295
6.1. Histamine-3 Receptor Antagonists 295
6.2. Ghrelin Antagonist 295
6.3. 11β-hydroxysteroid Dehydrogenase Type I Inhibitor 295
6.4. Modulators of Energy Sensing in the Brain (Acetyl Co-A Carboxylase 2 Inhibitor; Fatty Acid Synthase; Carnitine Palmitoyltransferase-3) 296
6.5. Adiponectin 296
6.6. Melanocortin-4 Receptor (MC4R) Agonists 296

7. Natural Products (over-the-counter Preparations) 297
7.1. Chromium 297
7.2. Garcinia cambogia 297
7.3. Chitosan 298
7.4. Hoodia 298
7.5. Stevia 298
7.6. Citrus aurantium 299

8. Summary and Conclusions 299
References 300
Chapter 17: Surgical Treatment of the Overweight Patient

George A. Bray

1. Introduction 307
2. Surgical Approaches to Obesity and Their Historical Context 309
3. Indications and Contraindications 310
   3.1. Indications in Adults 310
   3.2. Contraindications for Adults 310
   3.3. Bariatric Surgery for the Pediatric Age Group 311
4. Effectiveness of Surgical Procedures 312
5. Mechanisms for Weight Loss 315
6. Benefits from Bariatric Surgery 316
7. Complications Associated with Bariatric Surgery 318
   7.1. Complications Following Lap-band Bariatric Surgery 318
   7.2. Complications Following Restrictive Bariatric Surgery 318
   7.3. Complications with Malabsorptive Operations 319
8. Other Operative Procedures for the Overweight Patient 321
   8.1. Intragastric Balloon 321
   8.2. Gastric Stimulation or Gastric Pacing 321
   8.3. Liposuction and Omentectomy 321
9. Summary 322
   References 323

Index 329
Overweight and the Metabolic Syndrome:
From Bench to Bedside
Bray, G.A.; Ryan, D. (Eds.)
2006, XXII, 336 p. 80 illus., Hardcover